Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

13G Filing: Biotechnology Value Fund LP and CytomX Therapeutics Inc (CTMX)

Published on July 3, 2017 at 2:09 pm by Insider Monkey Staff in Hedge Funds

Page 1 of 13

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Biotechnology Value Fund	0		0	941,783	941,783	2.6%
Biotechnology Value Fund II	0		0	608,749	608,749	1.7%
Biotechnology Value Trading Fund OS	0		0	171,334	171,334	Less%
BVF Partners OS Ltd	0		0	171,334	171,334	Less%
BVF Partners	0		0	2,026,998	2,026,998	5.5%
BVF Inc	0		0	2,026,998	2,026,998	5.5%
Mark N. Lampert	0		0	2,026,998	2,026,998	5.5%

Page 1 of 13 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c),
AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No.
)¹

CytomX Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value

(Title of Class of Securities)

23284F 10 5

(CUSIP Number)

June 19, 2017

(Date of Event Which Requires Filing of this
Statement)

Check the appropriate box
to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☒

Rule 13d-1(c)

☐

Rule 13d-1(d)

1
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.

The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Follow Cytomx Therapeutics Inc. (NASDAQ:CTMX)

Follow Cytomx Therapeutics Inc. (NASDAQ:CTMX)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 13

NASDAQ:CTMX SEC 13G Filing Biotechnology Value Fund L P CytomX Therapeutics Inc. (CTMX)